Article
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Molecular cancer - 3 Feb 2015
Atefi Mohammad, Titz Bjoern, Avramis Earl, Ng Charles, Wong Deborah J L, Lassen Amanda, Cerniglia Michael, Escuin-Ordinas Helena, Foulad David, Comin-Anduix Begonya, Graeber Thomas G, Ribas Antoni
Abstract excerpt
BACKGROUND: Approximately 20% of melanomas contain a mutation in NRAS. However no direct inhibitor of NRAS is available. One of the main signaling pathways downstream of NRAS is the MAPK pathway. In this study we investigated the possibility of blocking oncogenic signaling of NRAS by inhibiting two signaling points in the MAPK pathway. METHODS: Fourteen NRAS mutated human melanoma cell lines were treated with a...
Topics
- Apoptosis
- Cell Cycle
- Cell Line, Tumor
- Cell Proliferation
- Cyclin D1
- Cyclin D3
- GTP Phosphohydrolases
- Glycogen Synthase Kinase 3
- Glycogen Synthase Kinase 3 beta
- Humans